BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kato S, Honda K. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer. Cancers (Basel) 2020;12:E1965. [PMID: 32707720 DOI: 10.3390/cancers12071965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Patel KK, Kashfi K. Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochem Pharmacol 2021;:114654. [PMID: 34129857 DOI: 10.1016/j.bcp.2021.114654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
2 Patel KK, Sehgal VS, Kashfi K. Molecular targets of statins and their potential side effects: Not all the glitter is gold. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174906] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Grunvald MW, Jacobson RA, Kuzel TM, Pappas SG, Masood A. Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int J Mol Sci. 2020;21:7651. [PMID: 33081107 DOI: 10.3390/ijms21207651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Oh Y, Kwon OS, Min SS, Shin YB, Oh MK, Kim M. Olfactory Detection of Toluene by Detection Rats for Potential Screening of Lung Cancer. Sensors (Basel) 2021;21:2967. [PMID: 33922694 DOI: 10.3390/s21092967] [Reference Citation Analysis]
5 Fukuda J, Ikezawa K, Nakao M, Okagaki S, Ashida R, Ioka T, Takada R, Yamai T, Fukutake N, Uehara H, Nagata S, Takahashi H, Tabuchi T, Tanaka S, Ohkawa K, Katayama K. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Cancers (Basel) 2021;13:502. [PMID: 33525645 DOI: 10.3390/cancers13030502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Vellan CJ, Jayapalan JJ, Yoong BK, Abdul-Aziz A, Mat-Junit S, Subramanian P. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review. Int J Mol Sci 2022;23:2093. [PMID: 35216204 DOI: 10.3390/ijms23042093] [Reference Citation Analysis]
7 Sato Y, Kobayashi T, Nishiumi S, Okada A, Fujita T, Sanuki T, Kobayashi M, Asahara M, Adachi M, Sakai A, Shiomi H, Masuda A, Yoshida M, Takeuchi K, Kodama Y, Kutsumi H, Nagashima K, Honda K. Prospective Study Using Plasma Apolipoprotein A2-Isoforms to Screen for High-Risk Status of Pancreatic Cancer. Cancers (Basel). 2020;12. [PMID: 32937962 DOI: 10.3390/cancers12092625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu R, Cheng L, Yang S, Liu Y, Zhu Z. iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin's Lymphoma. Front Oncol 2022;12:848286. [PMID: 35371990 DOI: 10.3389/fonc.2022.848286] [Reference Citation Analysis]
9 Honda K, Honda K. Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms. CBM 2022;33:503-12. [DOI: 10.3233/cbm-210198] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Du Y, Yao K, Feng Q, Mao F, Xin Z, Xu P, Yao J. Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer. J Oncol 2021;2021:6656337. [PMID: 33986805 DOI: 10.1155/2021/6656337] [Reference Citation Analysis]
11 Felix K, Honda K, Nagashima K, Kashiro A, Takeuchi K, Kobayashi T, Hinterkopf S, Gaida MM, Dang H, Brindl N, Kaiser J, Büchler MW, Strobel O. Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms. Int J Cancer 2021. [PMID: 34778955 DOI: 10.1002/ijc.33875] [Reference Citation Analysis]